When it comes to 2021, to simplify one especially complex set of scenarios, I will be watching what I call the three Cs with extreme care: COVID-19, China and climate. Nikkei Asia will provide comprehensive and thorough coverage of these three subjects because these are the three topics I expect to deliver the biggest changes affecting Asia over the next 12 months.
When it comes to COVID-19, I cannot find much cause for optimism. Let's take the United Kingdom, for example. The first country to approve the Pfizer-BioNTech vaccine, the U.K. began mass vaccinations on Dec. 8. It took only two weeks before skepticism dampened that early surge of hope after U.K. health authorities identified a new, more contagious variant of the virus.